Clinical trials: RANDOMIZED
Cervical Degenerative Disc Disease
Comparison of DISCOVER™ Artificial Cervical Disc and ACDF for Treatment of Cervical DDD (IDE Study)
This study is intended to treat patients with symptomatic degenerative disc disease at one level of the cervical spine. The patients will be randomized to the DISCOVER Artificial Cervical Disc (total disc replacement) or…
- Trial name
- NCT00432159
- Testing
- Cervical TDR, ACDF with plate
- Where
- 32 sites in United States, Australia and 1 more
- Volunteers
- 500 people
- Sponsor
- DePuy Spine
Cytomegalovirus Infections
Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients
The purpose of this research study is to investigate whether or not oral maribavir is safe and effective compared to oral ganciclovir for preventing CMV disease when administered for up to 14 weeks in patients who have had a…
- Trial name
- NCT00497796
- Testing
- maribavir, ganciclovir
- Where
- 55 sites in United States
- Volunteers
- 307 people
- Sponsor
- Shire
Obstructive Sleep Apnea
TheraPAP Equivalence Crossover Study
The present study, TheraEquivalence, is a Phase 2 crossover study designed to examine the efficacy and safety of TheraPAP (TPAP) vs. CPAP alone in the treatment of OSA.
- Trial name
- NCT06238362
- Testing
- TPAP, CPAP
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- SleepRes Inc.
Neuropathic Pain
Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain
This study is designed to investigate if pregabalin is effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma due to a traumatic or surgical event such as, for example, motor vehicle accident, fall…
- Trial name
- NCT01701362
- Testing
- pregabalin
- Where
- 156 sites in United States, Bulgaria and 11 more
- Volunteers
- 542 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Interstitial Lung Diseases
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
This study is open to adults with fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). People can join the study if they have been diagnosed with this condition within the last 3 years and are…
- Trial name
- NCT07540988
- Testing
- Nerandomilast
- Where
- 162 sites in United States, Argentina and 18 more
- Volunteers
- 466 people
- Sponsor
- Boehringer Ingelheim
HIV-1 Infection
A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (behavior in the body) of bevirimat administered for 15 days to HIV-positive individuals.
- Trial name
- NCT01097070
- Testing
- Bevirimat
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Myrexis Inc.
Hypoglycemia, Diabetes Mellitus, Type 1
Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics
This is a blinded, randomized crossover study to compare the safety and efficacy of G-Pen (glucagon injection) to Lilly Glucagon (glucagon for injection [rDNA origin]) for hypoglycemia rescue of adult patients with type 1…
- Trial name
- NCT02656069
- Testing
- G-Pen (glucagon injection), Lilly Glucagon (glucagon injection [rDNA origin])
- Where
- 7 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Xeris Pharmaceuticals
COPD Exacerbation Acute
A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease, that causes obstructed airflow from the lungs that causes persistent obstructive airflow limitation.
- Trial name
- NCT05400369
- Testing
- Sitafloxacin, Moxifloxacin Hydrochloride
- Where
- 18 sites in China
- Volunteers
- 140 people
- Sponsor
- Daiichi Sankyo
Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica, Dominant
A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene
A double-blind, randomized, intra-subject placebo-controlled, multicenter, multiple dose study, evaluating safety, proof of mechanism, preliminary efficacy and systemic exposure in subjects with confirmed DDEB or RDEB diagnosis…
- Trial name
- NCT03605069
- Testing
- QR-313
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 2 people
- Sponsor
- Phoenicis Therapeutics
Colitis, Ulcerative
An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
The purpose of this study is to evaluate the efficacy and safety of vedolizumab intravenous (IV) treatment compared to adalimumab subcutaneous (SC) treatment over a 52-week treatment period.
- Trial name
- NCT02497469
- Testing
- Vedolizumab, Adalimumab
- Where
- 330 sites in United States, Argentina and 32 more
- Volunteers
- 771 people
- Sponsor
- Takeda
Pruritus, Hemodialysis Patients with Moderate-to-Severe Pruritus
A Clinical Trial Evaluating the Efficacy and Safety of HSK21542 in Patients with Chronic Kidney Disease-Associated Pruritus
This is a multi-center, randomized, double-blind, placebo-controlled study. About 544 maintenance hemodialysis patients with moderate or above chronic kidney disease-associated pruritus are planned to be enrolled.
- Trial name
- NCT05135390
- Testing
- HSK21542
- Where
- 2 sites in China
- Volunteers
- 545 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Fatty Liver
A Study of JNJ-75220795 in Japanese Participants
The purpose of this study is to assess the safety and tolerability of single subcutaneous (SC) dose of JNJ-75220795 in Japanese participants.
- Trial name
- NCT05039710
- Testing
- JNJ-75220795
- Where
- 4 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Janssen Pharmaceutical K.K.
Graft-versus-Host Disease
Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease
The purpose of this study is to determine whether extracorporeal photoimmune therapy with UVADEX (ECP) added to standard therapy is effective in the treatment of chronic graft-versus-host disease (GvHD).
- Trial name
- NCT00054613
- Testing
- Methoxsalen, Extracorporeal Photopheresis
- Where
- 31 sites in United States, Australia and 10 more
- Volunteers
- 72 people
- Sponsor
- Mallinckrodt
PONV
US Phase III Study of APD421 in PONV
A comparison of the efficacy of APD421 and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.
- Trial name
- NCT01991860
- Testing
- APD421- Amisulpride for IV injection
- Where
- United States
- Volunteers
- 364 people
- Sponsor
- Acacia Pharma Ltd
Kidney Disease, Chronic
A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis
This study is open to adults with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in…
- Trial name
- NCT05213624
- Testing
- BI 764198
- Where
- 54 sites in United States, Australia and 8 more
- Volunteers
- 67 people
- Sponsor
- Boehringer Ingelheim
Septic Shock
ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber
The primary objective of this clinical investigation is to investigate the feasibility and possible benefits of the Alteco® LPS Adsorber in treating patients with septic shock with presumed endotoxemia of abdominal or urogenital…
- Trial name
- ASSET (NCT02335723)
- Testing
- Alteco LPS Adsorber
- Where
- 6 sites in Finland, Norway and 1 more
- Volunteers
- 15 people
- Sponsor
- Alteco Medical AB
Atopic Dermatitis, Eczema
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis
This trial will be a double-blind, randomized, placebo-controlled, safety, tolerability and efficacy trial of SAN007 (5% East Indian sandalwood oil in a cream formulation) treatment regimen when administered daily for up to 28…
- Trial name
- NCT02871479
- Testing
- SAN007 5% cream, SAN007 10% cream
- Where
- 5 sites in United States
- Volunteers
- 71 people
- Sponsor
- Santalis Pharmaceuticals, Inc.
Chronic Hepatitis B
A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B
The purpose of this study is to evaluate the safety and tolerability of JNJ-440 in healthy and Chronic Hepatitis B (CHB) participants after single and multiple doses; and to evaluate the pharmacokinetic (PK) of JNJ-440 in healthy…
- Trial name
- NCT03439488
- Testing
- JNJ-440
- Where
- 7 sites in Moldova, New Zealand and 3 more
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Healthy
Bioequivalence Study of Tipranavir Stored at Controlled Temperature Compared With Tipranavir Stored at Controlled Refrigerated Conditions, Orally Co-administered With Ritonavir in Healthy Male and Female Volunteers
The objective of this trial was to establish the bioequivalence of Tipranavir (TPV) 250 mg self emulsifying drug delivery system (SEDDS) capsules that had been stored at a controlled temperature of 30°C and controlled relative…
- Trial name
- NCT02253888
- Testing
- TPV - Room condition, TPV - Refrigerated conditions, Ritonavir (RTV)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Hypercholesterolemia
Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)
This study will evaluate the EZ/Ator fixed-dose combination (FDC) tablet (MK-0653C) as second line Low-Density Lipoprotein - Cholesterol (LDL-C) treatment in Chinese participants.
- Trial name
- NCT03768427
- Testing
- EZ 10 mg/Ator 10 mg, EZ 10 mg/Ator 20 mg, Atorvastatin
- Where
- 30 sites in China
- Volunteers
- 454 people
- Sponsor
- Organon and Co
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.